Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis

Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free su...

Full description

Bibliographic Details
Main Authors:	Alessandro Rizzo, Angela Dalia Ricci, Annarita Fanizzi, Raffaella Massafra, Raffaele De Luca, Giovanni Brandi
Format:	Article
Language:	English
Published:	MDPI AG 2023-01-01
Series:	Current Oncology
Subjects:	hepatocellular carcinoma atezolizumab bevacizumab immunotherapy cabozantinib sorafenib
Online Access:	https://www.mdpi.com/1718-7729/30/1/57

Similar Items

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
by: Young Eun Chon, et al.
Published: (2024-07-01)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
by: Maria Cerreto, et al.
Published: (2023-09-01)

Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018–2021) compared to the sorafenib era (2008–2018)
by: Chloe A. Lim, et al.
Published: (2024-07-01)

Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma
by: Chien-Yu Tseng, et al.
Published: (2023-11-01)

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
by: Sun Young Yim, et al.
Published: (2024-10-01)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
by: Tetsu Tomonari, et al.
Published: (2023-02-01)

Current hepatocellular carcinoma systemic pharmacological treatment options
by: A. Caturano, et al.
Published: (2023-05-01)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
by: Francesco Tovoli, et al.
Published: (2020-10-01)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
by: Tomoyuki Satake, et al.
Published: (2023-07-01)

Online searches for hepatocellular carcinoma drugs mirror prescription trends across specialties and changes in guideline recommendations
by: Philipp Berning, et al.
Published: (2024-02-01)

Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Tae Hyun Kim, et al.
Published: (2023-09-01)

Efficacy of Atezolizumab Plus Bevacizumab–Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma
by: Etsuko Moriyama, et al.
Published: (2024-09-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab versus Transarterial Chemoembolization Alone in Intermediate‐stage Hepatocellular Carcinoma: A Multicenter Retrospective Study
by: Zheng Y, et al.
Published: (2024-06-01)

First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
by: Sri Harsha Tella, et al.
Published: (2022-06-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021)Research in context
by: Daneng Li, et al.
Published: (2024-01-01)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
by: Kazuhiro Nouso, et al.
Published: (2023-09-01)

Thyroid Dysfunction after Atezolizumab and Bevacizumab Is Associated with Favorable Outcomes in Hepatocellular Carcinoma
by: Young Shin Song, et al.
Published: (2023-05-01)

Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Young Eun Chon, et al.
Published: (2024-10-01)

Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
by: Zili Hu, et al.
Published: (2024-11-01)

Efficacy of Atezolizumab Plus Bevacizumab Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Real-World Study
by: Shen X, et al.
Published: (2024-10-01)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
by: Yasuhito Mitsuyama, MD, et al.
Published: (2023-09-01)

The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
by: Shigeo Shimose, et al.
Published: (2023-06-01)

Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study
by: Joel W. Neal, MD, PhD, et al.
Published: (2024-10-01)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
by: Ryosuke Tsunemitsu, et al.
Published: (2023-06-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
by: Naoshi Nishida
Published: (2024-10-01)

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
by: Xiaoqiang Gao, et al.
Published: (2023-07-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
by: Francesco Tovoli, et al.
Published: (2018-01-01)

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab
by: Yasuto Takeuchi, et al.
Published: (2023-09-01)

A Case of Fibrolamellar Hepatocellular Carcinoma in Which Tumor Control Was Achieved by Re‐Administering Atezolizumab and Bevacizumab
by: Satoru Hagiwara, et al.
Published: (2024-12-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study
by: Fei Cao, et al.
Published: (2023-09-01)

Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria
by: Masamichi Kimura, et al.
Published: (2024-09-01)

Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants
by: Tasuku Nakabori, et al.
Published: (2024-06-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Letter regarding “Feasibility of additional radiotherapy in patients with advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab”
by: Sun Hyun Bae, et al.
Published: (2023-09-01)

Pretreatment Modified Albumin–Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma
by: Takashi Tanaka, et al.
Published: (2022-07-01)